,30, 31, 32 Further primary kidney end point trials with other agents in this class of medications in people with CKD are ongoing and include promising data from the dual GLP-1 RAs and GIP agonist, tirzepatide.33 The gene discussed is GIP; the disease is chronic kidney disease.